This Monday it was announced that Sputnik V has a high percentage of effectiveness according to the results of the third phase clinical trials.
3 min read
- The makers of Sputnik V have already applied for approval from the Mexican government to use their vaccine in the country.
According to the results of the third phase of the clinical studies carried out with the Russian vaccine (Sputnik V.) against him COVID-19Its effectiveness has been confirmed to be 91.4%, and in severe cases due to the coronavirus, 100%. The announcement was made on Monday by the Gamaleya National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF).
A declaration on the Sputnik V side also stipulated that the results of this research would be published by the Centro Gamaleya team in “one of the most important international medical journals”.
It is worth noting that the analysis was performed during the last checkpoint, that is, 21 days after the volunteers received the first component of Sputnik V. In addition, the results came from a “calculation based on analysis of the data from volunteers (n = 22,714) who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final checkpoint “. There were a total of 78 cases of people who got sick: 62 had received the placebo and 16 had received the vaccine.
Image: NurPhoto | Getty Images
For its part, the vaccine showed 100% effectiveness in severe cases: “Among the confirmed cases of coronavirus infection, 20 severe cases were registered in the placebo group, while no severe cases were registered in the group that received the vaccine,” confirmed the members of the RDFI and the Gamaleya Center.
Of the 26,000 volunteers who received the Russian vaccine, none have reportedly had adverse reactions. However, the volunteers will be monitored for at least six months after receiving the vaccine.
Meanwhile, Foreign Minister Marcelo Ebrad confirmed on the same Monday that the manufacturers of Sputnik V have already applied for approval from the Mexican government to use their vaccine in the country. The documentation was handed over to the Federal Commission for the Protection of Hygiene Risks (Cofepris), so it can be assumed that the clinical studies can begin soon.